Collegium Pharmaceutical Inc
NASDAQ:COLL

Watchlist Manager
Collegium Pharmaceutical Inc Logo
Collegium Pharmaceutical Inc
NASDAQ:COLL
Watchlist
Price: 31.19 USD 1.3% Market Closed
Market Cap: 1B USD
Have any thoughts about
Collegium Pharmaceutical Inc?
Write Note

Collegium Pharmaceutical Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Collegium Pharmaceutical Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Collegium Pharmaceutical Inc
NASDAQ:COLL
Total Current Assets
$443.8m
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Total Current Assets
$53.2B
CAGR 3-Years
-4%
CAGR 5-Years
4%
CAGR 10-Years
-1%
Bristol-Myers Squibb Co
NYSE:BMY
Total Current Assets
$28.1B
CAGR 3-Years
-4%
CAGR 5-Years
-7%
CAGR 10-Years
7%
Pfizer Inc
NYSE:PFE
Total Current Assets
$37.8B
CAGR 3-Years
-13%
CAGR 5-Years
2%
CAGR 10-Years
-4%
Merck & Co Inc
NYSE:MRK
Total Current Assets
$40.4B
CAGR 3-Years
9%
CAGR 5-Years
9%
CAGR 10-Years
2%
Eli Lilly and Co
NYSE:LLY
Total Current Assets
$31.4B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
10%
No Stocks Found

Collegium Pharmaceutical Inc
Glance View

Market Cap
1B USD
Industry
Pharmaceuticals

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The company is headquartered in Stoughton, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2015-05-07. Collegium is a diversified, specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The firm's product portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR (Nucynta Products), which are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Xtampza ER is formulated using its abuse-deterrent technology platform, DETERx. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

COLL Intrinsic Value
47.46 USD
Undervaluation 34%
Intrinsic Value
Price

See Also

What is Collegium Pharmaceutical Inc's Total Current Assets?
Total Current Assets
443.8m USD

Based on the financial report for Sep 30, 2024, Collegium Pharmaceutical Inc's Total Current Assets amounts to 443.8m USD.

What is Collegium Pharmaceutical Inc's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
12%

Over the last year, the Total Current Assets growth was -17%. The average annual Total Current Assets growth rates for Collegium Pharmaceutical Inc have been 7% over the past three years , 12% over the past five years .

Back to Top